Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 9 December 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares closed at a new 52-week low of ₹23.55, marking a significant daily loss and reflecting a broader sentiment of panic selling among investors.

Mangalam Drugs and Organics has reached a new 52-week low price of Rs.23.77, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed its sector peers and broader market indices, reflecting persistent challenges in its financial performance and market valuation.

Mangalam Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and operational challenges. This shift highlights the company's current standing amid a difficult market environment and deteriorating fundamentals.

Shares of Mangalam Drugs and Organics Ltd surged to hit the upper circuit limit on 4 December 2025, reflecting robust buying interest and a maximum permissible daily gain of 5%. The stock closed at ₹25.40, marking a significant turnaround after a prolonged period of decline, and outperformed its sector and benchmark indices amid notable market activity.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 3 December 2025, reflecting intense selling pressure and a continuation of a prolonged downtrend. The stock recorded its new 52-week low at ₹23.94, marking a significant decline amid subdued investor participation and unfilled supply on the order books.

Mangalam Drugs and Organics has reached a new 52-week low of Rs.24.08, marking a significant decline amid a sustained period of negative returns and financial pressures. The stock’s recent performance highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, as it continues to trade well below key moving averages and underperform its benchmark indices.

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 2 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical and biotechnology company’s shares closed at a new 52-week low of Rs 25.20, marking a maximum daily loss of 5.01%, significantly underperforming its sector and the broader market indices.

Mangalam Drugs and Organics Ltd is currently experiencing severe selling pressure, marked by a complete absence of buyers and a persistent decline in its share price. The stock has recorded consecutive losses over an extended period, signalling distress selling within the Pharmaceuticals & Biotechnology sector.

Mangalam Drugs and Organics has reached a fresh 52-week low of Rs.25.85, marking a significant decline amid an extended period of negative returns and underperformance relative to its sector and broader market indices.

Mangalam Drugs and Organics Ltd has encountered severe selling pressure, with the stock hitting a fresh 52-week low and registering a day’s decline of 4.99%, significantly underperforming the broader market and its sector peers. The absence of buyers and a persistent downtrend highlight distress selling signals that have intensified over recent months.

Mangalam Drugs and Organics has reached a new 52-week low of Rs.26.67, marking a significant decline amid a sustained downward trajectory over the past several months. The stock’s recent performance contrasts sharply with broader market trends, highlighting ongoing challenges within the company’s financial and operational landscape.

Mangalam Drugs and Organics Ltd witnessed a significant downturn on 1 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical and biotechnology company’s shares closed at a new 52-week low of ₹26.53, marking a maximum daily loss of 2.86%, underperforming both its sector and the broader market indices.

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 28 Nov 2025, hitting its lower circuit price limit of ₹27.93. The stock faced intense selling pressure, resulting in a maximum daily loss of 5.03%, marking a new 52-week low and continuing a prolonged downtrend that has seen the share price fall by over 55% in the past ten trading sessions.

Mangalam Drugs and Organics has reached a new 52-week low of Rs.28.07, marking a significant decline amid a sustained period of negative returns. The stock has experienced a notable downtrend over the past several weeks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Mangalam Drugs and Organics Ltd has experienced severe selling pressure, with the stock hitting a fresh 52-week low of Rs. 28.07 today. The pharmaceutical company’s shares have been on a steep downward trajectory, marked by a continuous absence of buyers and a persistent stream of sell orders, signalling distress in the market.

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 27 Nov 2025, hitting its lower circuit limit with a maximum daily loss of 10.01%, reflecting intense selling pressure and a significant drop in investor confidence within the Pharmaceuticals & Biotechnology sector.

Mangalam Drugs and Organics has reached a fresh 52-week low of Rs.29.54, marking a significant decline amid an extended period of negative returns. The stock’s recent performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Mangalam Drugs and Organics Ltd has experienced a severe downturn in trading activity, marked by relentless selling pressure and an absence of buyers. The stock has recorded a sharp decline today, hitting a new 52-week low and continuing a prolonged streak of losses that starkly contrasts with broader market gains.

Mangalam Drugs and Organics Ltd has encountered severe selling pressure, with the stock hitting a fresh 52-week low of Rs. 32.82 today. The pharmaceutical and biotechnology company’s shares have recorded consecutive declines over the past week, reflecting a distressing trend of sustained investor sell-off and absence of buying interest.